Galapagos

• Galapagos has sold a portfolio of small molecule programmes in oncology and immunology to Onco3R Therapeutics in exchange for Onco3R equity and future milestone-based considerations 
• The programmes involve a Phase 1-ready SIK3 inhibitor for immunology indications, as well as a precision oncology portfolio featuring small molecule candidates targeting among others FGFR3, SMARCA2, and P53 Y220C 
• The sale to Onco3R highlights Galapagos’ strategic transformation, following its January 2025 announcement to discontinue its small molecule discovery programmes and seek potential partners, in order to focus on long-term value creation in cell therapy 
• This transactions further builds on Van Lanschot Kempen's decade-long relationship with Galapagos, which began with leading Galapagos’ Euronext IPO in May 2005 and continued through several follow-on and M&A transactions, including the divestment of Jyseleca to Alfasigma in 2024

Galapagos is a global biotechnology company with operations in Europe, the Unites States and Asia, dedicated to transforming patient outcomes through life-changing science and innovation. The company focuses on areas of high unmet medical need, combining compelling science, technology, and collaborative approaches to build a robust pipeline of best-in-class medicines in oncology and immunology, including a decentralised T-cell manufacturing network.

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Co-Manager in the USD 748 million capital increase by Abivax
• Joint Bookrunner in the USD 201 million capital increase by Pharvaris 
• Financial Adviser in Maat Pharma’s €36 million venture debt facility from the European Investment Bank
• Lead Manager in the USD 345 million capital increase by Merus
• Co-Placement Agent in DBV Technologies’ up to USD 307 million financing
• Placement Agent in MaaT Pharma’s €13 million capital increase
• Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
• Sole Financial Adviser in GENFIT’s royalty financing up to €85 million
• Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
• Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma
• Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank